Is the robot-assisted procedure the future of MIGS?

Article

Robot-assisted surgical precision offers less than 5-µm precision tremor stabilization, 1 to 10-mN force-sensing smart instrumentation and automated procedure-specific guidance and assistance with analytics.

Is the robot-assisted procedure the future of MIGS?

Image courtesy of New York Eye and Ear Infirmary of Mount Sinai.

Investigators from the Icahn School of Medicine at Mount Sinai, New York, United States, reported that robot-assisted microinterventional glaucoma surgery (MIGS) has potential for interventions in the anterior segment, according to Dr Gautam Kamthan, Assistant Director of Ophthalmic Innovation and Technology at New York Eye and Ear Infirmary of Mount Sinai. They reported the first such feasibility of robot-assisted ophthalmic gonio-surgery.

Dr Kamthan and co-investigators studied the potential for use of this approach by comparing robotic interventions preclinically to the standard manual approach in synthetic eye models for MIGS. Three robotic systems have been developed by theNew York Eye and Ear Robotics Program: the µ-RoboticGonio Surgery System, the T-Rexµ-RoboticFlexible Goniotomy and iStentµ-Robotic Implantation System.

A comparison of the surgical precision between manual and surgical procedures speaks to the rationale for robotic-assisted procedure. Manual procedures are characterized by 100-µm tremor peak-to-peak vector magnitude, 500 to 1,000-mN human finger force sensing resolution and 182-µm root mean square tremor amplitude with manual vitreoretinal surgery, Dr Kamthan explained.

In contrast, robot-assisted surgical precision offers less than 5-µm precision tremor stabilization, 1 to 10-mN force-sensing smart instrumentation and automated procedure-specific guidance and assistance with analytics.

In MIGS, robotics would enhance the safety and efficacy of the procedures. “Precision matters for small devices,” he emphasized.

In support of this, Dr Ianchulev, Professor of Ophthalmology, Director of Ophthalmic Innovation and Technology at New York Eye and Ear Infirmary of Mount Sinai, noted that 30% of iStents (Glaukos) are malpositioned according to an FDA Safety Report.

The doctors used the nonimplantable goniotomy intervention in Phase 1 of the study and trabecular stent implantation with the iStent inject W in Phase 2. The main outcome was anatomically successful goniointervention.

During the Phase 1 segment, Dr Kamthan reported that they performed consecutive trials of complete ab interno goniotomy robotically and manually for at least 90 degrees using a standard goniotomy knife. An ab interno goniotomy exceeding 150 degrees was achieved using the flexible, guided microinterventional goniotomy instrument.

During the Phase 2 segment, the iStent inject W device was deployed successfully in 10 trials within the trabecular meshwork in all of the attempts both manually and robotically.

Based on these results, the investigators concluded, “A system for robot-assisted MIGS can successfully achieve interventions in the anterior segment. This is the first demonstration of the feasibility of robot-assisted ophthalmic gonio-surgery.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.